The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Experimental therapy of PC-3 and DU-145 human androgen-independent prostate cancers with targeted cytotoxic analog of somatostatin an-162.
Ferenc Rick
No relevant relationships to disclose
Andrew Abi-Chaker
No relevant relationships to disclose
Luca Szalontay
No relevant relationships to disclose
Norman L. Block
No relevant relationships to disclose
Gabor Halmos
No relevant relationships to disclose
Andrew V. Schally
No relevant relationships to disclose